Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

829 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors.
Ji H, Zhao X, Yuza Y, Shimamura T, Li D, Protopopov A, Jung BL, McNamara K, Xia H, Glatt KA, Thomas RK, Sasaki H, Horner JW, Eck M, Mitchell A, Sun Y, Al-Hashem R, Bronson RT, Rabindran SK, Discafani CM, Maher E, Shapiro GI, Meyerson M, Wong KK. Ji H, et al. Among authors: shimamura t. Proc Natl Acad Sci U S A. 2006 May 16;103(20):7817-22. doi: 10.1073/pnas.0510284103. Epub 2006 May 3. Proc Natl Acad Sci U S A. 2006. PMID: 16672372 Free PMC article.
The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.
Minami Y, Shimamura T, Shah K, LaFramboise T, Glatt KA, Liniker E, Borgman CL, Haringsma HJ, Feng W, Weir BA, Lowell AM, Lee JC, Wolf J, Shapiro GI, Wong KK, Meyerson M, Thomas RK. Minami Y, et al. Among authors: shimamura t. Oncogene. 2007 Jul 26;26(34):5023-7. doi: 10.1038/sj.onc.1210292. Epub 2007 Feb 19. Oncogene. 2007. PMID: 17311002
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.
Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, Mahmood U, Mitchell A, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Kim W, Jänne PA, Shapiro GI, Tenen D, Johnson BE, Weissleder R, Sharpless NE, Wong KK. Ji H, et al. Among authors: shimamura t. Cancer Cell. 2006 Jun;9(6):485-95. doi: 10.1016/j.ccr.2006.04.022. Epub 2006 May 25. Cancer Cell. 2006. PMID: 16730237 Free article.
Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy.
Li D, Shimamura T, Ji H, Chen L, Haringsma HJ, McNamara K, Liang MC, Perera SA, Zaghlul S, Borgman CL, Kubo S, Takahashi M, Sun Y, Chirieac LR, Padera RF, Lindeman NI, Jänne PA, Thomas RK, Meyerson ML, Eck MJ, Engelman JA, Shapiro GI, Wong KK. Li D, et al. Among authors: shimamura t. Cancer Cell. 2007 Jul;12(1):81-93. doi: 10.1016/j.ccr.2007.06.005. Cancer Cell. 2007. PMID: 17613438 Free article.
Heat shock protein 90 inhibition in lung cancer.
Shimamura T, Shapiro GI. Shimamura T, et al. J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S152-9. doi: 10.1097/JTO.0b013e318174ea3a. J Thorac Oncol. 2008. PMID: 18520302 Free PMC article. Review.
Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance.
Shimamura T, Li D, Ji H, Haringsma HJ, Liniker E, Borgman CL, Lowell AM, Minami Y, McNamara K, Perera SA, Zaghlul S, Thomas RK, Greulich H, Kobayashi S, Chirieac LR, Padera RF, Kubo S, Takahashi M, Tenen DG, Meyerson M, Wong KK, Shapiro GI. Shimamura T, et al. Cancer Res. 2008 Jul 15;68(14):5827-38. doi: 10.1158/0008-5472.CAN-07-5428. Cancer Res. 2008. PMID: 18632637 Free PMC article.
829 results